EUVIMEDEUVIMED entdecken
Fallbericht

Myelodysplasia cutis and VEXAS syndrome initially diagnosed as histiocytoid Sweet syndrome: A diagnostic pitfall

Serena J Shimshak iD, Sion Jasmine, Mark D P Davis, Emma F Johnson, Margot S Peters, Gang Zheng, Olayemi Sokumbi iD, Nneka I Comfere

Journal of Cutaneous Pathology · 2024-11 · 51 (11) · 834-839

DOI: 10.1111/cup.14678 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Cutaneous Pathology, online erschienen am 12.07.2024. Verfasst von Serena J Shimshak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Mayo Clinic, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Sweet Syndrome, Myelodysplastic Syndromes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histiocytoid Sweet syndrome (H‐SS) is a histopathological variant of Sweet syndrome (SS) defined by cutaneous infiltration of immature myeloid cells morphologically resembling histiocytes. The association of H‐SS with underlying malignancy, particularly myelodysplastic syndromes, is well‐established. Myelodysplasia cutis (MDS‐cutis) has been proposed to describe cases historically diagnosed as H‐SS but characterized by shared clonality of the myeloid infiltrate in skin and bone marrow. Therefore, identifying patients who might have MDS‐cutis is critical for the management of the associated hematologic malignancy. VEXAS syndrome, an adult‐onset autoinflammatory disease, should also be included in the histopathologic differential diagnosis of H‐SS, as it shares clinical and pathologic features with MDS‐cutis. Through the presentation of two cases, we aim to highlight the defining features and key clinical implications of MDS‐cutis and VEXAS syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sweet SyndromeMyelodysplastic SyndromesHumansDiagnosis, DifferentialMaleHistiocytesMiddle AgedFemaleAgedSkin

Stichwörter der Autor:innen

Sweet syndromeVEXAS syndromemyelodysplasia cutismyelodysplastic syndromes

Autor:innen und Institutionen

  • Department of Dermatology, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Georgia Dermatology Partners, Atlanta, Georgia, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.

ORCID-Profile: Serena J Shimshak, Olayemi Sokumbi

Zitieren

APA

Shimshak, S. J., Jasmine, S., Davis, M. D. P., Johnson, E. F., Peters, M. S., Zheng, G., Sokumbi, O., & Comfere, N. I. (2024). Myelodysplasia cutis and VEXAS syndrome initially diagnosed as histiocytoid Sweet syndrome: A diagnostic pitfall. Journal of Cutaneous Pathology, 51(11), 834-839. https://doi.org/10.1111/cup.14678

Vancouver

Shimshak SJ, Jasmine S, Davis MDP, Johnson EF, Peters MS, Zheng G, et al. Myelodysplasia cutis and VEXAS syndrome initially diagnosed as histiocytoid Sweet syndrome: A diagnostic pitfall. Journal of Cutaneous Pathology. 2024;51(11):834-839. doi:10.1111/cup.14678

BibTeX
@article{Shimshak2024,
  author = {Shimshak, Serena J and Jasmine, Sion and Davis, Mark D P and Johnson, Emma F and Peters, Margot S and Zheng, Gang and Sokumbi, Olayemi and Comfere, Nneka I},
  title = {Myelodysplasia cutis and VEXAS syndrome initially diagnosed as histiocytoid Sweet syndrome: A diagnostic pitfall},
  journal = {Journal of Cutaneous Pathology},
  year = {2024},
  volume = {51},
  number = {11},
  pages = {834--839},
  doi = {10.1111/cup.14678}
}
Kostenlos starten →